Deals channel feed

Ro­bot­ic pill mak­er Rani teams up with Chugai in deal worth up to $1.08B

Yesterday
R&D

Roche inks $80M up­front deal for Han­soh’s can­cer ADC

Yesterday
China

White House makes new ‘most fa­vored na­tion’ deal, shares up­dates on FDA vouch­ers, GLP-1 ne­go­ti­a­tions

Yesterday
Pharma

I-Mab re­makes it­self, with plans for Hong Kong list­ing, reti­nal R&D, and a new name

2 days ago
Financing
China

Pre­gene strikes pact with Kite worth up to $1.52B for in vi­vo ther­a­pies

2 days ago
China
Cell/Gene Tx

Mer­ck KGaA is open to more ac­qui­si­tions, but not for its CD­MO unit

2 days ago
Manufacturing

No­vo Nordisk buys kid­ney, blood dis­or­der drug from Omeros

3 days ago
Pharma

Post-Hoc Live: Are the good times in biotech … back?

3 days ago
Financing

Which big phar­ma has the busiest BD team? You might be sur­prised

3 days ago
Bioregnum

J&J CEO down­plays any need for 'large' ac­qui­si­tion as it gears up for new launch­es

4 days ago
Pharma

BioCryst to ac­quire As­tria for $700M, adding a sec­ond HAE drug

4 days ago

Up­dat­ed: John­son & John­son to spin out or­tho­pe­dics busi­ness

4 days ago
Pharma

Ex­clu­sive: Bris­tol My­ers, in­sitro ex­tend re­search deal to find a drug for new ALS tar­get

4 days ago
AI

Take­da ex­pands de no­vo pro­tein re­search by sign­ing sec­ond deal with AI spe­cial­ist Nabla Bio

4 days ago
AI

Is the worst over? Bio­phar­ma deal­mak­ing shows an uptick in third quar­ter

5 days ago
Bioregnum

J&J is in dis­cus­sions to buy out Pro­tag­o­nist Ther­a­peu­tics — re­port

Last week
Pharma

Bris­tol My­ers joins in vi­vo CAR-T race with $1.5B Or­bital ac­qui­si­tion

Last week
Pharma
Cell/Gene Tx

Ex­clu­sive: Ot­su­ka Pre­ci­sion Health buys ma­ter­nal med­i­ta­tion plat­form Mind­ful Ma­mas

Last week
Startups
Health Tech

Up­dat­ed: No­vo Nordisk to buy MASH play­er Akero for $4.7B up­front

Last week
R&D

In $2B biobucks pact, Zenas snags MS drug that Bio­gen re­turned to In­no­Care

Last week
China

Met­sera got less than it want­ed from Pfiz­er in long-await­ed obe­si­ty biotech ac­qui­si­tion

Last week
Pharma

Ar­bor part­ners with Chiesi Group in gene edit­ing deal with po­ten­tial $2B fu­ture pay­ments

Last week
Cell/Gene Tx

Be­hind-the-scenes de­tails of 89bio's $2.4B deal with Roche

3 weeks ago
Pharma

Gala­pa­gos says it’s weeks away from de­ci­sion on cell ther­a­py busi­ness re­view

3 weeks ago
Cell/Gene Tx
1234 Next page Last page
A service from the Financial Times